Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Green AK, Zhou Q, Iasonos A, Zammarrelli WA, Weigelt B, Ellenson LH, Chhetri-Long R, Shah P, Loh J, Hom V, Selenica P, Erinjeri J, Petkovska I, Chandarlapaty S, Cohen S, Grisham R, Konner J, Rubinstein MM, Tew W, Troso-Sandoval T, Aghajanian C, Makker V. Green AK, et al. Among authors: zammarrelli wa. Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. Online ahead of print. Clin Cancer Res. 2024. PMID: 39561275
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer.
Gómez-Banoy N, Ortiz EJ, Jiang CS, Dagher C, Sevilla C, Girshman J, Pagano AM, Plodkowski AJ, Zammarrelli WA, Mueller JJ, Aghajanian C, Weigelt B, Makker V, Cohen P, Osorio JC. Gómez-Banoy N, et al. Among authors: zammarrelli wa. J Clin Invest. 2024 Jun 20;134(17):e180516. doi: 10.1172/JCI180516. J Clin Invest. 2024. PMID: 38900575 Free PMC article.
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer.
Gómez-Banoy N, Ortiz E, Jiang CS, Dagher C, Sevilla C, Girshman J, Pagano A, Plodkowski A, Zammarrelli WA, Mueller JJ, Aghajanian C, Weigelt B, Makker V, Cohen P, Osorio JC. Gómez-Banoy N, et al. Among authors: zammarrelli wa. medRxiv [Preprint]. 2024 Jun 9:2024.06.07.24308618. doi: 10.1101/2024.06.07.24308618. medRxiv. 2024. Update in: J Clin Invest. 2024 Jun 20;134(17):e180516. doi: 10.1172/JCI180516 PMID: 38883775 Free PMC article. Updated. Preprint.
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA 3rd, Ma W, Espino K, Gordhandas S, Yeoshoua E, Ehmann S, Zhou Q, Iasonos A, Abu-Rustum NR, Aghajanian C, Green AK, Rubinstein MM, Makker V. Zammarrelli WA 3rd, et al. Gynecol Oncol. 2023 Nov;178:27-35. doi: 10.1016/j.ygyno.2023.09.010. Epub 2023 Sep 23. Gynecol Oncol. 2023. PMID: 37748268 Free PMC article.
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Ehmann S, Shay K, Zhou Q, Iasonos A, Sonoda Y, Gardner GJ, Long Roche K, Zammarrelli WA 3rd, Yeoushoua E, O'Cearbhaill RE, Zivanovic O, Chi DS. Ehmann S, et al. Among authors: zammarrelli wa 3rd. Gynecol Oncol. 2023 Feb;169:118-124. doi: 10.1016/j.ygyno.2022.12.009. Epub 2022 Dec 22. Gynecol Oncol. 2023. PMID: 36565685 Free PMC article. Review.
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification.
Zammarrelli WA 3rd, Kim SH, Da Cruz Paula A, Rios-Doria EV, Ehmann S, Yeoshoua E, Hanlon EJ, Zhou Q, Iasonos A, Alektiar KM, Aghajanian C, Makker V, Leitao MM Jr, Abu-Rustum NR, Ellenson LH, Weigelt B, Mueller JJ. Zammarrelli WA 3rd, et al. JCO Precis Oncol. 2022 Oct;6:e2200194. doi: 10.1200/PO.22.00194. JCO Precis Oncol. 2022. PMID: 36240474 Free PMC article.
Connect the Dots-January 2019.
Eubanks AAC, Zammarrelli WA, Lee JK, Chescheir NC. Eubanks AAC, et al. Among authors: zammarrelli wa. Obstet Gynecol. 2019 Jan;133(1):183-184. doi: 10.1097/AOG.0000000000003036. Obstet Gynecol. 2019. PMID: 30531581 No abstract available.